Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.

Etanercept, infliximab and adalimumab have shown clinical benefit in immune-mediated inflammatory diseases; however, the outcome of treatment with these tumour-necrosis factor inhibitors remains insufficient in approximately 40-60% and approximately 25-40% of individuals with rheumatoid arthritis and Crohn's disease, respectively. Moreover, their use is accompanied by adverse events and unintentional immune suppression. Pharmacogenetics has the potential to increase efficacy and ameliorate adverse events and immune suppression, and its application might be of clinical benefit for patients with rheumatoid arthritis and Crohn's disease. Pharmacogenetic studies have shown associations between single nucleotide polymorphisms in genes encoding enzymes related to the pharmacodynamics of these drugs and treatment outcome. As we discuss here, replication and prospective validation are warranted before pharmacogenetics can be used in clinical practice.

[1]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[2]  B. Mougin,et al.  The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population , 2005, Annals of the rheumatic diseases.

[3]  J. Belaiche,et al.  Tumour necrosis factor (TNF) gene polymorphism influences TNF‐α production in lipopolysaccharide (LPS)‐stimulated whole blood cell culture in healthy humans , 1998, Clinical and experimental immunology.

[4]  J. Lanchbury.  The HLA association with rheumatoid arthritis. , 1992, Clinical and experimental rheumatology.

[5]  J. Belaiche,et al.  Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism , 2002, Scandinavian journal of gastroenterology.

[6]  D. Hommes,et al.  Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.

[7]  J. O'dell,et al.  Treating rheumatoid arthritis early: a window of opportunity? , 2002, Arthritis and rheumatism.

[8]  M. Lazarus,et al.  An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[9]  J. O'dell,et al.  Therapeutic strategies for rheumatoid arthritis. , 2004, The New England journal of medicine.

[10]  J. Belaiche,et al.  No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease , 2006, Pharmacogenetics and genomics.

[11]  P. V. van Riel,et al.  Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. , 2004, Arthritis and rheumatism.

[12]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[13]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[14]  S. Bae,et al.  The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. , 2005, Rheumatology.

[15]  S. Targan,et al.  ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. , 2001, Gastroenterology.

[16]  Y. Goltsev,et al.  Tumor necrosis factor receptor and Fas signaling mechanisms. , 1999, Annual review of immunology.

[17]  T. Dassopoulos,et al.  Evolving treatment strategies for inflammatory bowel disease. , 2001, Annual review of medicine.

[18]  H. Hakonarson,et al.  Advances in the development of genetic markers for the diagnosis of disease and drug response , 2002, Expert review of molecular diagnostics.

[19]  J. Belaiche,et al.  NOD2/CARD15 does not influence response to infliximab in Crohn's disease. , 2002, Gastroenterology.

[20]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[21]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[22]  J. Smolen,et al.  Therapeutic strategies in early rheumatoid arthritis. , 2005, Best practice & research. Clinical rheumatology.

[23]  J. Hampe,et al.  Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. , 2002, Pharmacogenetics.

[24]  H. Tiwari,et al.  The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. , 2004, Arthritis and rheumatism.

[25]  D. Pisetsky,et al.  Associations, populations, and the truth: recommendations for genetic association studies in Arthritis & Rheumatism. , 2004, Arthritis and rheumatism.

[26]  L. Criswell,et al.  The shared epitope and severity of rheumatoid arthritis. , 2002, Rheumatic diseases clinics of North America.

[27]  H. Khamis,et al.  Simple solution to a common statistical problem: interpreting multiple tests. , 2004, Clinical therapeutics.

[28]  J. Fonseca,et al.  Polymorphism at position –308 of the tumour necrosis factor α gene and rheumatoid arthritis pharmacogenetics , 2005, Annals of the rheumatic diseases.

[29]  G. Assmann,et al.  Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[30]  B. Cronstein,et al.  Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis , 2005, Pharmacological Reviews.

[31]  T. Pincus,et al.  Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[32]  E. G. de la Concha,et al.  IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. , 2005, World journal of gastroenterology.

[33]  Van Deventer,et al.  Tumour necrosis factor and Crohn's disease. , 1997 .

[34]  P. Hasleton,et al.  Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. , 1998, Transplantation.

[35]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[36]  P. Lipsky,et al.  Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. , 2004, Arthritis and rheumatism.

[37]  P. Shekelle,et al.  How to read radiographs according to the Sharp/van der Heijde method. , 1999 .

[38]  Thomas Pap,et al.  Arthritis , 2000, Nature Biotechnology.

[39]  R. Deutsch,et al.  Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α–blocking agents , 2005 .

[40]  P. Rutgeerts,et al.  Tumour necrosis factor‐α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab , 2004, Alimentary pharmacology & therapeutics.

[41]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[42]  S. Hanauer,et al.  An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease , 2004, American Journal of Gastroenterology.

[43]  F. O'Gara,et al.  Tumour necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families , 2001, Genes and Immunity.

[44]  J. Belaiche,et al.  A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism , 2002 .

[45]  A. Aguirre,et al.  Tumour necrosis factor‐α (TNF‐α) levels and influence of −308 TNF‐α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis , 2004 .

[46]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[47]  S. Targan,et al.  Role of cytokines in the pathogenesis of inflammatory bowel disease. , 2000, Annual review of medicine.

[48]  Rheumatoid arthritis: the goal rather than the health-care provider is key , 2006, The Lancet.

[49]  J. Belaiche,et al.  Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease , 2004, Alimentary pharmacology & therapeutics.

[50]  C. Ackerley,et al.  Epitope shared by functional variant of organic cation/carnitine transporter, OCTN1, Campylobacter jejuni and Mycobacterium paratuberculosis may underlie susceptibility to Crohn's disease at 5q31. , 2005, Biochemical and biophysical research communications.

[51]  A. Zinsmeister,et al.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.

[52]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[53]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.

[54]  Wei Chen,et al.  Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. , 2002, American journal of human genetics.

[55]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.

[56]  L. Klareskog,et al.  Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital , 2005 .

[57]  J. Hampe,et al.  Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab , 2002, The Pharmacogenomics Journal.

[58]  É. Albuisson,et al.  IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjögren's syndrome and rheumatoid arthritis. , 1998, Clinical immunology and immunopathology.

[59]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[60]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[61]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[62]  D. Boumpas,et al.  Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[63]  J. Cohen,et al.  The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.

[64]  L. Cardon,et al.  Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. , 2002 .

[65]  Nathalie Balandraud,et al.  Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[66]  D. MacEwan.  TNF receptor subtype signalling: differences and cellular consequences. , 2002, Cellular signalling.

[67]  Judy H. Cho,et al.  [Letters to Nature] , 1975, Nature.

[68]  D. Felson,et al.  ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. , 1999, The Journal of rheumatology.

[69]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[70]  E. Veys,et al.  Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. , 2003, Arthritis and rheumatism.

[71]  D. Felson,et al.  ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials : Part 3: Rheumatoid Arthritis: Response , 1998 .

[72]  C. Ware.  Network communications: lymphotoxins, LIGHT, and TNF. , 2005, Annual review of immunology.

[73]  N. Olsen,et al.  New drugs for rheumatoid arthritis. , 2004, The New England journal of medicine.

[74]  Tanja Stamm,et al.  Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. , 2005, Arthritis and rheumatism.

[75]  T. Huizinga,et al.  Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus , 1999, Genes and Immunity.

[76]  Michel Eichelbaum,et al.  Pharmacogenomics and individualized drug therapy. , 2006, Annual review of medicine.

[77]  D. D. de Jong,et al.  Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. , 2003, The Netherlands journal of medicine.

[78]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[79]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[80]  D. M. van der Heijde,et al.  Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results , 2005, Annals of the rheumatic diseases.

[81]  L. Padyukov,et al.  Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[82]  Xiao-Yu Song,et al.  Binding and functional comparisons of two types of tumor necrosis factor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[83]  R. Panaccione,et al.  Advances in medical therapy of inflammatory bowel disease. , 2005, Current opinion in pharmacology.

[84]  Maarten Boers,et al.  The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. , 2004, Arthritis and rheumatism.

[85]  P. Rutgeerts,et al.  Etanercept in the treatment of active refractory Crohn’s disease: a single-center pilot trial , 2001 .

[86]  E. G. de la Concha,et al.  Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. , 2004, Arthritis and rheumatism.

[87]  M. King,et al.  Tumor necrosis factor a microsatellite polymorphism is associated with rheumatoid arthritis severity through an interaction with the HLA-DRB1 shared epitope. , 1999, Arthritis and rheumatism.

[88]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.